EQUITY ALERT Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Neurotrope, Inc. – NTRP
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Neurotrope, Inc. securities (NASDAQ:NTRP) from January 7, 2016 through April 28, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Neurotrope investors under the federal securities laws.
To join the Neurotrope class action, go to http://www.rosenlegal.com/cases-1133.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose material adverse information regarding the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope announced “positive top-line results” of the focal Phase 2b trials of Bryostatin-1, mentioning “improvement in patients with moderate to severe Alzheimer's disease,” The trial data allegedly negates these statements as the top-line data relating to the 20 microgram dose of Bryostatin-1 did not produce statistically significant results. Neurotrope also allegedly failed to disclose statements about the efficacy of the 40 microgram dose in connection with its primary and secondary endpoints. On this news, shares of Neurotrope fell from $18.81 per share on April 28, 2017 to a close at $6.97 per share on May 1, 2017, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 17, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1133.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.